|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Francisco Partners, a technology-focused private equity firm. |
|---|---|
| Transferring Party | QuadraMed Corporation (QDHC), a provider of healthcare information technologies. |
| Sector | Data Management/ Healthcare IT |
| Date | December 8, 2009 |
| Analysis New platform for Francisco Partners. Operating as a private company enables QuadraMe to focus on operations not short-term results for the public markets. The deal is attractive given the emphasis on IT in healthcare reform and the availability of stimulus funds for the sector. The company provides integrated, workflow-driven solutions for clinicians, patient information retrieval systems, revenue cycle solutions and electronics records and document management products, among other things. Deal value -- $126m, a 33% stock price premium. QuadraMed's TTM revenue and EBITDA were $126m and $14m, respectively. There is no financing condition, but Wells Fargo and Silicon Valley Bank have committed to provide debt financing. This is Francisco's 5th separate healthcare IT investment. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |